Publications by authors named "J Fagin"
The 2022 World Health Organization classification introduced the term high-grade follicular cell-derived nonanaplastic thyroid carcinoma (HGFCTC) to define invasive/infiltrative nonanaplastic thyroid carcinoma with high-grade features, including poorly differentiated thyroid carcinoma and high-grade differentiated thyroid carcinoma. Our objectives were to compare clinicopathological characteristics, oncologic outcomes, and mutation profiles among HGFCTC subgroups to better inform prognostication and treatment. In this single-center, retrospective cohort study of 252 patients who had surgery for HGFCTC from 1986 to 2020, we categorized HGFCTC and its related entity, "encapsulated noninvasive neoplasms of follicular cells with high-grade features," into five subgroups: (A) encapsulated noninvasive, (B) encapsulated with capsular invasion only (minimally invasive), (C) encapsulated angioinvasive with focal vascular invasion (VI), (D) encapsulated angioinvasive with extensive VI, and (E) infiltrative tumors.
View Article and Find Full Text PDFThyroid nodules are a common endocrine condition with an increasing incidence over the decades. Data-independent acquisition has been widely utilized in discovery proteomics to identify disease biomarkers and therapeutic targets. To analyze the thyroid disease-related proteome in a high-throughput, reproducible and reliable manner, we introduce thyroid-specific peptide spectral libraries.
View Article and Find Full Text PDFAnaplastic thyroid cancer (ATC) is a clinically aggressive malignancy with a dismal prognosis. Combined BRAF/MEK inhibition offers significant therapeutic benefit in patients with -mutant ATCs. However, relapses are common and overall survival remains poor.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness of Fluorine 18-labelled tetrafluoroborate ([F]TFB) as an imaging alternative to iodine for assessing metastatic thyroid cancer and potential radioiodine treatment success.
- Five patients participated in the research, receiving both [F]TFB and iodine imaging on the same day. Results showed that [F]TFB identified 58% of lesions compared to 91% for iodine imaging, indicating its lower sensitivity.
- The conclusion drawn highlights that [F]TFB did not successfully predict iodine uptake in patients undergoing redifferentiation therapy, raising questions about its reliability for other treatment cases or in untreated patients.
Article Synopsis
- The clinical development of farnesyltransferase inhibitors (FTIs) for HRAS-mutant tumors shows varied responses due to co-occurring mutations and their impact on sensitivity to FTIs.
- Targeted sequencing revealed that HRAS-mutant cancers frequently exhibit mutations in the MAPK, PI3K, or RTK pathways, more so than KRAS and NRAS mutants, with specific alterations like BRAF, NF1, PTEN, and PIK3CA being prevalent.
- Research indicated that while certain comutations confer resistance to FTIs, combining FTIs with MEK inhibitors may enhance sensitivity in HRAS-mutant tumors, presenting a potential treatment strategy.